Medy-Tox’s affiliate Numeco secured regulatory approval in Thailand for its botulinum toxin product Newlux, marking the treatment’s second international market entry after Peru. The December 26 approval positions the Korean biotech firm to strengthen its foothold in Southeast Asia’s growing cosmetic surgery market.
The Thai Food and Drug Administration’s green light comes as Medytox seeks approvals in more than 20 countries, building on its established presence in Thailand where its Meditox product has led the local toxin market since 2013. The company resumed Meditox sales last year following a three-year pause.
Thailand’s medical tourism sector, known for competitive pricing, presents a strategic opportunity for Numeco. The company plans to diversify its portfolio by combining Newlux with its hyaluronic acid fillers, Atiere and Neuramis, the latter already commanding significant market share in Thailand.
Manufactured at Medy-Tox’s Osong Plant No. 3, Newlux represents part of the company’s broader push to capture a larger slice of the global botulinum toxin market. CEO Ju Hee-seok noted that the Thai approval marks a significant step in the company’s international expansion strategy.
The cosmetic treatment market in Thailand continues to attract both domestic and international clients, driven by competitive pricing and established medical infrastructure.
